A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
In this randomized, cross-over, open label study the correlation of Pegasys (peginterferon alfa-2a) pharmacokinetics after intravenous (iv) and subcutaneous (sc) administration with viral load and viral kinetics will be investigated in patients with chronic hepatitis C genotype 1 who were non-responders to previous standard combination therapy with pegylated interferon and ribavirin. Patients will be randomized to receive either weekly or twice weekly Pegasys iv or sc for 2 weeks, crossing over to the other mode of administration after a washout period of 6 weeks.
Pharmacokinetics and Pharmacodynamics of Intravenous Administration of Pegylated Interferon-2a in Patients With Chronic Hepatitis C and Previous Non-response to Standard Combination Therapy With Pegylated Interferon and Ribavirin (Intervention Study)
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult caucasian patients, 18 - 70 years of age
Hepatitis C, genotype 1
Non-responder to previous anti-HCV therapy with peginterferon alfa and ribavirin
Compensated liver disease (Child-Pugh class A) for >/= 24 months before baseline
Positive for anti-HCV for > 6 months, with detectable serum HCV-RNA
Treatment-naïve or responder to previous therapy
HCV infection other than genotype 1
Positive for Hepatitis A, Hepatitis B or HIV infection at screening
Chronic Hepatitis of other than HCV origin
Decompensated liver disease (Child-Pugh class B or C)
Therapy with systemic antiviral, antineoplastic or immunomodulatory agents in the 6 months prior to study
Clinically relevant retina disorder
Pregnant or lactating women and male partners of pregnant women